Literature DB >> 16226745

Interferon and the central nervous system.

Nachum Dafny1, Pamela B Yang.   

Abstract

Interferons (IFNs) were discovered as natural antiviral substances produced during viral infection and were initially characterized for their ability to "interfere" with viral replication, slow cell proliferation, and profound alteration of immunity. The IFNs are synthesized and secreted by monocytes, macrophages, T-lymphocytes, neurons, and glia cells. The different IFNs are classified into three classes: alpha, beta, and gamma. alpha-IFN produced in the brain exerts direct effects on the brain and endocrine system by activating the neurosecretory hypothalamic neurons and regulates the hypothalamic-pituitary-adrenocortical axis. IFNs modulate neurophysiological activities of many brain region involving in pain, temperature, and food intake regulation. alpha-IFN administration activates the sympathetic nerves innervating components of the immune system. IFNs may serve as regulatory mediators between the central nervous system, the immune system, and endocrine system. IFN is used as immunologic therapy to treat various hematologic malignancies and infectious ailments and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226745     DOI: 10.1016/j.ejphar.2005.08.029

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

1.  A confocal and electron microscopic comparison of interferon beta-induced changes in vesicular stomatitis virus infection of neuroblastoma and nonneuronal cells.

Authors:  Paul M D'Agostino; Carol Shoshkes Reiss
Journal:  DNA Cell Biol       Date:  2010-03       Impact factor: 3.311

Review 2.  Cytokine interactions with adrenal medullary chromaffin cells.

Authors:  Shirley A Douglas; Dharshini Sreenivasan; Fiona H Carman; Stephen J Bunn
Journal:  Cell Mol Neurobiol       Date:  2010-11-19       Impact factor: 5.046

3.  DISTINCT MECHANISMS OF INHIBITION OF VSV REPLICATION IN NEURONS MEDIATED BY TYPE I AND TYPE II IFN.

Authors:  Paul M D'Agostino; Jingjun Yang; Carol Shoshkes Reiss
Journal:  Virus Rev Res       Date:  2009-01-01

Review 4.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

5.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

6.  Interferon-stimulated gene 15 as a general marker for acute and chronic neuronal injuries.

Authors:  Ren-Gang Wang; Marcus Kaul; Dong-Xian Zhang
Journal:  Sheng Li Xue Bao       Date:  2012-10-25

Review 7.  Neuroimmunology of central nervous system viral infections: the cells, molecules and mechanisms involved.

Authors:  Carine Savarin; Cornelia C Bergmann
Journal:  Curr Opin Pharmacol       Date:  2008-06-16       Impact factor: 5.547

8.  IFN-beta-induced alteration of VSV protein phosphorylation in neuronal cells.

Authors:  Paul M D'agostino; Jessica J Amenta; Carol Shoshkes Reiss
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

9.  Glial restricted precursors maintain their permissive properties after long-term expansion but not following exposure to pro-inflammatory factors.

Authors:  Kazuo Hayakawa; Christopher Haas; Ying Jin; Julien Bouyer; Takanobu Otsuka; Itzhak Fischer
Journal:  Brain Res       Date:  2015-10-21       Impact factor: 3.252

10.  Interferon-gamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells.

Authors:  Johanna Mäkelä; Raili Koivuniemi; Laura Korhonen; Dan Lindholm
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.